Retrospective analysis of fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide.

被引：1
|
作者：
Sridhar, Srikala S.
Smith, Alan D.
Fallah-Rad, Nazanin
Hansen, Aaron Richard
机构：
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Hosp, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.374
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
374
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [22] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [23] Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer
    Mason, Malcolm
    EUROPEAN UROLOGY, 2018, 74 (06) : 845 - 845
  • [24] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
  • [25] Overall survival by race in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
    McNamara, Megan Ann
    George, Daniel J.
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Baser, Onur
    Huang, Ahong
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [26] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Dikshyanta Rana
    Claudia Geue
    Kelly Baillie
    Jiafeng Pan
    Tanja Mueller
    Jennifer Laskey
    Marion Bennie
    Julie Clarke
    Robert J. Jones
    Ailsa Brown
    Olivia Wu
    PharmacoEconomics - Open, 2022, 6 : 303 - 313
  • [27] Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Hoang, Anh
    Karlou, Maria
    Ashe, Robynne
    Tu, Shi Ming
    Aparicio, Ana
    Troncoso, Patricia
    Mohler, James
    Logothetis, Christopher J.
    EUROPEAN UROLOGY, 2015, 67 (01) : 53 - 60
  • [28] Enzalutamide in Castration-Resistant Prostate Cancer
    Anker, Markus S.
    Lehmann, Lorenz H.
    Anker, Stefan D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1380 - 1380
  • [29] Enzalutamide in castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (08): : E312 - E312
  • [30] Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide
    Takemura, Kosuke
    Ito, Masaya
    Nakanishi, Yasukazu
    Kataoka, Madoka
    Sakamoto, Kazumasa
    Suzuki, Hiroaki
    Tobisu, Ken-ichi
    Koga, Fumitaka
    ANTICANCER RESEARCH, 2019, 39 (10) : 5773 - 5780
12345